This study offers compassionate access to a special treatment for people who have had a stem cell transplant (SCT) but are experiencing poor or no graft function. This means your body isn't making enough new blood cells after the transplant. The treatment involves an infusion of CD34 positive stem cells, which are collected from a donor's blood and then specially selected using a Miltenyi device. These selected cells are the early immune cells your body needs to rebuild its immune system. The goal is to see if this infusion can improve your graft function within 4 weeks. You will receive Tylenol (acetaminophen) and Benadryl (diphenhydramine hydrochloride) before the infusion to help prevent side effects. The study plans to enroll 200 participants.

Study design

This is an interventional study providing compassionate access to a specific treatment. It aims to enroll 200 participants.

What's involved

You will receive an infusion of CD34 positive stem cells by vein, which will last about 10-30 minutes. Before the infusion, you will be given Tylenol and Benadryl.

Compensation

Not stated in the trial record.

Follow-up

Your graft function will be measured at 4 weeks after the infusion to assess the treatment's success.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.